ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence.

Paul Aisen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.